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Abstract
Background Facioscapulohumeral dystrophy (FSHD) is caused by mutations leading to the aberrant expression of the
DUX4 transcription factor in muscles. DUX4 was proposed to induce cell death, but the involvement of different death
pathways is still discussed. A possible pro-apoptotic role of DUX4 was proposed, but as FSHD muscles are characterized
by necrosis and inflammatory infiltrates, non-apoptotic pathways may be also involved.
Methods We explored DUX4-mediated cell death by focusing on the role of one regulated necrosis pathway called
necroptosis, which is regulated by RIPK3. We investigated the effect of necroptosis on cell death in vitro and in vivo ex-
periments using RIPK3 inhibitors and a RIPK3-deficient transgenic mouse model.
Results We showed in vitro that DUX4 expression causes a caspase-independent and RIPK3-mediated cell death in
both myoblasts and myotubes. In vivo, RIPK3-deficient animals present improved body and muscle weights, a reduction
of the aberrant activation of the DUX4 network genes, and an improvement of muscle histology.
Conclusions These results provide evidence for a role of RIPK3 in DUX4-mediated cell death and open new avenues of
research.
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Introduction
Facioscapulohumeral dystrophy (FSHD) is characterized by a
loss of repressive epigenetic marks within the D4Z4 microsat-
ellite located in the sub-telomeric region of chromosome 4.1–3
In muscle, this chromatin relaxation, when associated with a
permissive chromosome 4 carrying the ATTAAA
polyadenylation signal, results in the expression of the DUX4
transcription factor whose ORF is present in each D4Z4 re-
peat, resulting in a poison protein effect through induction
of multiple downstream genes.4,5 DUX4 expression is
extremely low, but it has been robustly found in adult and
foetal FSHD muscle cells and biopsies.6–8 DUX4 was proposed
to disrupt multiple cellular functions (for review, see
DeSimone et al.9) and to induce cell death in different models.
Several publications have reported DUX4-mediated cell death
in vitro in murine C2C12 or human myotubes10–12 and in vivo
in different species including mice.13,14 However, the mecha-
nisms leading to cellular death still need to be deciphered,
and the involvement of p53-mediated apoptosis has been
discussed.13,15 Recently, DUX4 was also described to cause
pathological accumulation of hyaluronic acid leading to
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caspase-3/7 activation and cell death,16 to lead to cytotoxicity
mediated by a global accumulation of acetylated histone H3
that can be improved by the addition of specific p300
inhibitors,17 and to activate the cellular hypoxia signalling
pathway responsible for cell death.18
Here, we investigated the role of regulated necrosis in
DUX4-mediated toxicity. Indeed, the concept of cell death
has considerably evolved over the past 20 years, and cell
death can be divided in non-programmed cell death or necro-
sis, which mainly occurs in response to accidental cell death,
as opposed to programmed cell death, which is composed of
autophagy, apoptosis, and programmed/regulated necrosis
(for review, see previous works19,20). We focused on the most
studied form of regulated necrosis called necroptosis, which
has emerged as a major pathological process in many dis-
eases including neurologic, cardiovascular, pulmonary, and
gastrointestinal systems (for review, see Khoury et al.20).
Necroptosis was initially defined as a receptor-interacting
protein kinases 1 and 3 (RIPK1 and RIPK3)-dependent molec-
ular cascade that is regulated by multiple steps of
post-transcriptional modifications including phosphorylation
and ubiquitination,21 leading in particular to the
pseudokinase mixed-lineage kinase domain-like (MLKL) phos-
phorylation and its translocation to the membrane and the
disruption of the plasma membrane (for review, see Silke
et al.22). Here, we show that necroptosis contributes to
DUX4-mediated toxicity both in vitro and in vivo. We used
the iC2C12-DUX4 cells that carry a doxycycline (dox)-induc-
ible DUX4 transgene10 and observed that DUX4 expression
causes a RIPK1-mediated or a RIPK3-mediated necroptosis
in either iC2C12-DUX4 myoblasts or myotubes, respectively.
In vivo, the cre-inducible DUX4 transgenic mouse model23 de-
ficient in RIPK324 had reduced muscle and body weight loss
following DUX4 expression, a reduced activation of DUX4 net-
work genes, and an improved muscle histology. This study
thus provides evidence for a key role of necroptosis in
DUX4-mediated cell death.
Methods
Animals housing and crosses
Mice were bred in the Biological Services Unit of the Great
Ormond Street Institute of Child Health and University Col-
lege London in accordance with the Animals (Scientific Proce-
dures) Act 1986, under Home Office Licence 70/8389. All
experiments were performed following the United Kingdom
and European guidelines (Directive 2010/63/UE of the Euro-
pean Parliament and of the Council) and approved by rele-
vant committees. The FLExDUX4 (B6(Cg)-Gt(ROSA)
26Sortm1.1(DUX4*)Plj/J) and HSA-Cre (B6.Cg-Tg(ACTA1-cre/
Esr1)2Kesr/J) mice were purchased from the Jackson
Laboratory (#028710, #025750) and were crossed to generate
the Cre(+/)FLExDUX4(+/) mice (named CD/Cre+ and CD/
Cre in the manuscript). RipK3-KO mice (C57BL/6 Ripk3
+/) were originally kindly provided by Geentech (San
Francisco, CA) to generate Mdx/RipK3(/) mice and then
crossed back to remove the mdx mutation.25 These three
strains were crossed to generate Cre(+/)RipK3(/) and
FLExDUX4(+/+)RipK3(/) mice and bred together to generate
progeny Cre(+/)FLExDUX4(+/)RipK3(/)/Cre(/)
FLExDUX4(+/)RipK3(/) (CDR/Cre+ and CDR/Cre, respec-
tively) used in the experiments. Mice were genotyped as
previously described.26
Three-week-old animals were weighted three times a
week, after weaning. The tamoxifen (MP Biomedicals)
injections were realized according to Jones and Jones.23
Six-week-old mice were injected (IP) with tamoxifen on two
consecutive days for a final concentration of 10 mg/kg.
Following tamoxifen injection, animals were daily weighed
and sacrificed after a week. Muscles were harvested and
frozen in liquid nitrogen or liquid-nitrogen-cooled isopentane
for further analysis.
Treadmill exhaustion test
The test consisted of an acclimatization period of 5 min on
the treadmill (set to an angle of 15°), followed by 5 min at
5 m/min. The speed was then increased by 0.5 m every min-
ute. Electric shock on the treadmill was removed, and mice
were encouraged to run by gently pushing them. Mice refus-
ing to run for 10 s were removed from the treadmill, and the
total running time was recorded.
Cell culture, viability, cytotoxicity, and caspase
activation
Inducible iC2C12-Dux410 were cultured in Dulbecco’s modi-
fied Eagle’s medium high glucose with GlutaMAX and no So-
dium Pyruvate (Gibco), 20% foetal bovine serum (FBS), and
800 μg/mL G418 (Gibco). For myoblast experiments,
iC2C12-Dux4 were seeded into white 96-well plates (3000
cells per well) in growth medium. After 24 h, DUX4 expres-
sion was induced by adding doxycycline (Sigma-Aldrich) at a
final concentration of 50 to 1000 ng/mL. For myotubes exper-
iments, iC2C12-Dux4 were seeded into white 96-well plates
(1500 cells per well) in growth medium. After 48 h, cells were
differentiated with Dulbecco’s modified Eagle’s medium, 2%
horse serum, and 10 μg/mL insulin. DUX4 expression was in-
duced after 4 days of differentiation to not disturb myotube
formation.10 Inhibition of apoptosis and/or necroptosis was
simultaneously realized to DUX4 induction for 24 h using
20 μM of pan-caspase inhibitor Z-VAD.fmk (Merk Chemicals),
30 μM necrostatin-1, 3 μMGSK872, and 0.2 μM cyclosporin A
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(Cambridge Bioscience). Cell survival was determined by
CellTiter-Glo luminescent cell viability assay (Promega), mem-
brane permeability by CytoTox-Glo cytotoxicity assay
(Promega), and caspase activation by Caspase-Glo 3/7 Assay
(Promega) according to the manufacturer’s instructions. Lu-
minescence was read by a microplate reader (infinite
200Pro, Tecan, Switzerland).
RNA extraction and quantitative PCR
Total RNAs from cells were extracted using Trizol (Thermo
Fisher) according to the manufacturer’s protocol. Reverse
transcription was performed on 1 μg of total RNA in a
10 μL final volume (Roche Transcriptor First-Strand cDNA
Synthesis Kit). Quantitative PCR was designed according to
the MIQE standards. Quantitative PCRs were performed on
a LightCycler 480 Real-Time PCR System (Roche) in a final
volume of 9 μL with 0.2 μL of RT product, 0.4 μM each
of forward and reverse primers (Supporting Information,
Table S1), and 4.5 μL of SYBRGreen Mastermix (Roche).
Fusion index
The fusion index was performed as previously described.27
Briefly, the cells were plated at 2.4 K/well in 96-well plates.
Two days later, proliferation medium was replaced by differ-
entiation medium. The cultures were fixed with 100% EtOH,
and MF20 staining was performed (MF20, mouse IgG2b,
1:20 dilution; Developmental Studies Hybridoma Bank). The
fusion index was calculated by counting the number of nuclei
in MF20-positive myotubes as a percentage of the total num-
ber of nuclei.
Histological and immunofluorescence analysis
Histological and immunofluorescence analysis was performed
on 10 μm transverse cryosections from the quadriceps mus-
cle. Sections were stained with haematoxylin and eosin, or
different Ab. For IgG uptake, the protocol was adapted from
Straub et al.28 Sections stored at 80°C were dried at room
temperature for 30 min and fixed with 4% paraformaldehyde
for 10 min. Following three washes with phosphate buffered
saline, staining areas were delimited using a Dako pen. Sam-
ples were incubated in 20% FBS, 0.5% Tween 20, 0.5% Triton
X100 (except for IgG uptake), and 5% bovine serum albumin.
Primary antibodies were diluted in 1% FBS and incubated 2 h
at room temperature (IgG uptake analysis) or overnight at
4°C (CD68 positive cells infiltration analysis). Secondary anti-
bodies were diluted in 1% FBS and incubated for 1 h at room
temperature, and sections were stained for nuclei with
Hoechst for 15 min. For immunofluorescence analysis, rat
IgG2A antibody to CD68 (clone FA-11, BioLegend #137001,
1/50), mouse antibody to Laminin (Dako #Z0097, 1/400), goat
anti-mouse IgG (Biotin-XX, Invitrogen, 1/400), mouse anti-rat
IgG2A eFluor 615 Texas Red (1/400), goat anti-rabbit Alexa
Fluor 488 (1/400), and Streptavidin Protein, DyLight 488
(1/400) were used.
Pictures were acquired using ThermoScientific™
Invitrogen™ EVOS™ FL Auto 2 Imaging System and 20× objec-
tives. Sections were entirely scanned, and pictures were
analysed using ImageJ software.
Statistical analysis
GraphPad Prism software was used for statistical analyses.
Differences between groups were evaluated by either a
one-way analysis of variance followed by Dunnett’s or
Tukey’s post hoc tests or a T-test as indicated in the figure
legends. ****: P < 0.0001; ***: P < 0.001; **: P < 0.01; *:
P < 0.05.
Results
DUX4 expression causes Ripk1-mediated
necroptosis in iC2C12-DUX4 myoblasts
To investigate the role of necroptosis in DUX4 toxicity, we
used the iC2C12-DUX4 cells that carry a doxycycline (dox)-in-
ducible DUX4 transgene.10 In the presence of dox, DUX4 is
expressed in a dose-dependent manner (Figure 1A), and con-
sequently, genes downstream of DUX4 are transcribed
(Figures 1B and S1), and cell viability dramatically decreased
(19.3 ± 1.2% of viable cells at 1000 ng/ml of dox) (Figure 1C).
Non-induced cells expressed low levels of the three major
genes involved in necroptosis Ripk1, RipK3, and Mlkl, but
after DUX4 induction, expression increased up to 2.52 ± 0.67
times for Ripk1, 1.83 ± 0.69 for Mlkl, and 3.7 ± 1.34 for Ripk3
(Figure 1D–1F, respectively).
We next asked whether increased necroptosis gene levels
have any effect on cell viability. First, we investigated the role
of the caspases by cultivating the iC2C12-DUX4 cells in the
presence of 200 ng/mL of dox (dose leading to an important
expression of DUX4 with a cell viability of 35%; Figure 1A and
1C) and with different doses of Z-VAD, a pan-caspase inhibi-
tor. No change in cell survival was observed with and without
Z-VAD (Figure 2A), indicating that caspases are not involved
in the death of the iC2C12-DUX4 cells. It is worth noting that
the addition of Z-VAD induced a non-specific increase of cell
survival that is due to the presence of DMSO (Figure S2A).
We confirmed that caspase 3/7 activity increased after
DUX4 expression and was correctly inhibited in the presence
of Z-VAD (Figure S2B). We next investigated the role of
necroptosis in the DUX4-mediated cell death by the addition
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of either necrostatin-1 (RIPK1 inhibitor) or GSK’872 (RIPK3 in-
hibitor) alone or in combination. The iC2C12-DUX4 viability
was assessed for two different doses of dox, and the results
are expressed as the percentage of cells alive in the presence
of the different compounds compared with the condition
without them. Z-VAD was always added to eliminate any bias
linked to caspases 3/7 activation/synergic effect. The only
condition that induced a cell rescue was when necrostatin-1
was present. In the presence of 100 ng/mL of dox, the two
combinations Z-VAD/necrostatin-1 and Z-VAD/necrostatin-1/
cyclosporine A lead to an increase of cell survival by
22 ± 15% (P = 0.06; Figure 2B). Similar results were obtained
when the dox concentration was 200 ng/mL (increase of cells
survival by 34 ± 20%, P = 0.011 when necrostatin-1 is pres-
ent), thus demonstrating the role of Ripk1-mediated
necroptosis in DUX4-mediated cell death in iC2C12-DUX4
myoblasts.
DUX4 expression causes RIPK3-mediated
necroptosis in iC2C12-DUX4 myotubes
We next investigated DUX4-mediated toxicity in iC2C12-DUX4
myotubes. An MF20 staining was realized to assess myotube
formation, and we calculated that the fusion index was 20.3%
(Figure S3). We observed an increase of DUX4mRNA after ad-
dition of dox in a dose-dependent manner (Figure 3A), asso-
ciated with an increase of several genes downstream of DUX4
including Tm7sf4 (Figure 3B),Wfdc3, Duxbl, and Snx30 (Figure
S4) and a decrease in cell viability (Figure 3C). The expression
Figure 1 DUX4 expression triggers cell death in iC2C12-DUX4 myoblasts. (A, B, D–F) Expression of DUX4, Tm7sf4, Ripk1, Mlkl, or Ripk3, respectively
(RT-qPCR) 24 h after addition of different concentration of dox in iC2C12-DUX4 myoblasts. (C) Cell viability assay [adenosine triphosphate (ATP) assay]
at 24 h after dox induction at various concentrations. Data represent the mean ± standard deviation on three independent experiments; ****:
P < 0.0001; ***: P < 0.001; **: P < 0.01; *: P < 0.05 by one-way analysis of variance with Dunnett’s post hoc test.
Figure 2 Necroptosis participates in DUX4-mediated cell death. (A) Cell viability on iC2C12-DUX4 myoblasts at 48 h of induction without or with dox
(200 ng/mL) and treatment with various concentrations of the pan-caspase inhibitor Z-VAD. (B) ATP assay on iC2C12-DUX4 myoblasts at 48 h of induc-
tion with 100 or 200 ng/mL of dox and treatment with different molecules (Z: ZVAD 20 μM, N: necrostatin-1 30 μM; G: GSK’872 2 μM; C: cyclosporin A
0.2 μM) alone or in combination. Data are presented as means ± standard deviation; *: P < 0.05 by one-way analysis of variance with Dunnett’s post
hoc test.
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of Ripk1 and Mlkl was not affected by DUX4 expression (Fig-
ure 3D and 3E). Ripk3 level was increased up to 1.9 ± 0.5-fold
(Figure 3F).
We next analysed the effects of the different inhibitors on
iC2C12-DUX4 myotubes. Again, the results are expressed as
the percentage of live cells in the presence of the different
compounds compared with the control condition without.
We observed no effect of Z-VAD arguing against a major role
of caspases in DUX4-mediated toxicity (Figure 4A). When the
cells were cultivated with necrostatin-1 in the presence of
dox (1000 ng/mL), necrostatin-1 concentrations above
60 μM conferred a good protection against cell death (up
to 60 ± 6% of viable cells in the presence of 60 μM
necrostatin-1 compared with 39 ± 1% without, P < 0.0001;
Figure 4A), necrostatin-1 concentrations of 150 or 300 μM
leading to up to 85 ± 2% viable cells (Figure 4A). When the
iC2C12-DUX4 myotubes were incubated with GSK’872, a mas-
sive cell death rescue was observed at low concentrations (up
to 67 ± 2% of viable cells in the presence of 3 μM GSK’872
compared with 39 ± 1% without, P < 0.0001; Figure 4A).
Higher GSK’872 concentrations slightly improved cell viability
(up to 77 ± 4% of viable cells in the presence of 6 μM
GSK’872, P < 0.0001; Figure 4A). These results demonstrated
the role of necroptosis in DUX4-mediated myotube death.
The different compounds were next added separately or to-
gether to iC2C12-DUX4 myotubes that were incubated with
dox (1000 ng/mL). No modification of the cell viability was
observed in the presence of 20 μM Z-VAD/30 μM
necrostatin-1, but when necrostatin-1 concentration was in-
creased to 90 μM (N+), the combination 20 μM Z-VAD/
90 μM necrostatin-1 leads to cell rescue (increase of cell sur-
vival by 54 ± 20% with necrostatin-1 compared with 10 ± 10%
for Z-VAD alone). The best cell rescue was observed in the
presence of GSK’872. Indeed, at low (2 μM, G) or high
(4 μM, G+) concentration, GSK’872 increased cell viability
by 2.1-fold (Figure 4B). The combination necrostastin-1/
GSK’872 did not show any additive or synergistic effect. These
results demonstrated the important role of necroptosis in
DUX4-mediated cell death. RIPK3, but also to a lesser extent
RIPK1, participated in DUX4-mediated cell toxicity.
Figure 3 DUX4 expression triggers cell death in iC2C12-DUX4 myotubes. (A, B, D–F) Expression of DUX4, Tm7sf4, Ripk1, Mlkl, or Ripk3, respectively
(RT-qPCR) 24 h after addition of different concentration of dox in iC2C12-DUX4 myotubes after 4 days of differentiation. (C) Cell viability assay [aden-
osine triphosphate (ATP) assay] at 24 h after dox induction at various concentrations. Data represent the mean ± standard deviation on three inde-
pendent experiments; ****: P < 0.0001; ***: P < 0.001; **: P < 0.01; *: P < 0.05 by one-way analysis of variance with Dunnett’s post hoc test.
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Necroptosis participates in DUX4-mediated toxicity
in vivo
The experiments performed in cell culture suggested that
necroptosis is a key element of DUX4-mediated toxicity. To
evaluate the role of necroptosis in vivo, we used the
cre-inducible DUX4 transgenic mouse model (FLExDUX4, here
called CD) that conditionally expresses human DUX4 follow-
ing tamoxifen injection.23 We crossed this model with a
Ripk3-deficient mouse model,24 leading to the new trans-
genic CDR (DUX4/+Ripk3/Cre-positive or -negative)
mouse model (Figure S5). After tamoxifen injection, total
body weight was measured, and Figure 5A represents the
variation of the total body weight gain (in percentage) from
the beginning of treatment to animal death. In CD- and
CDR-cre-negative animals, a 13–15% increase of the total
body weight was observed (Figure 5A), but in both CD- and
CDR-cre-positive animals, a decrease of the total body weight
was noted. This decrease is less pronounced in the CDR ani-
mals (in males, 91.4 ± 3.9% for the CDR/Cre+ and
84.6 ± 4.8% for the CD/Cre+, P = 0.02; in females,
90.8 ± 6.7% for the CDR/Cre+ and 82.5 ± 4.9% for the CD/
Cre+, P = 0.1). These results indicate the role of necroptosis
in DUX4-mediated toxicity leading to weight loss. We also
performed a treadmill exhaustion test on both the CDR/cre
+ and CD/Cre+ males (Figure 5B), which revealed that the
CDR-cre+ animals were able to run four times longer than
the Ripk3-competent animals (P = 0.055).
We next analysed the weights of the tibialis anterior (TA)
and quadriceps (QUA). CD- and CDR-Cre-negative animals
showed similar TA or QUA muscle weights (Figure 5C and
5D); CD- and CDR-Cre-positive animals showed also compara-
ble weights of the TA (~25 mg for the males and ~20–22 mg
for the females). However, QUA weights were higher in CDR-
Figure 4 Ripk3 inhibition decreased DUX4-mediated cell death in iC2C12-DUX4 myotubes. (A) iC2C12-DUX4 viability in the presence of dox 1000 ng/
mL and treated with different doses of Z-VAD, necrostatin-1, or GSK’872. (B) Cell viability in the presence of dox 1000 ng/mL with the different com-
pounds alone or in combination. Z: Z-VAD (20 μM), N: necrostatin-1 (30 μM), N+: necrostatin-1 (90 μM), G: GSK’872 (2 μM); G+: GSK’872 (4 μM). Data
are presented as means ± standard deviation; ****: P < 0.0001; ***: P < 0.001; **: P < 0.01; *: P < 0.05 by one-way analysis of variance with
Dunnett’s post hoc test.
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Cre-positive than in CD-Cre-positive animals (in males,
99.4 mg ± 6.6 for the CDR/Cre+ and 90.9 mg ± 8.4 for the
CD/Cre+, P = 0.02; in females, 87.3 mg ± 6.2 for the CDR/
Cre+ and 73.8 mg ± 6 for the CD/Cre+, P = 0.006), showing
that QUA weights are higher when RIPK3 is not expressed.
We examined morphological and physiological aspects of
the QUA only because variation in muscle weight was not ob-
served in the TA of mice expressing or not RIPK3. The mea-
sure of the minimal Feret’s diameter revealed the presence
of smaller fibres in the CD/Cre+ than in the CDR/Cre+ mice
(Figure 5E and 5F), which is in accordance with the reduced
muscle weight in the Ripk3-competent animals. We also cal-
culated the min Feret/Feret ratio to analyse fibre circularity
(Figure 5G). This ratio was higher in the CD/Cre+ group
(P = 0.017), showing a lower loss of the normal polygonal
myofibre shape in the Ripk3-deficient animals. The roundness
of the fibres was clearly visible on standard histological stain-
ing with haematoxylin and eosin, which revealed major histo-
logical changes in both CD/Cre+ and CDR/Cre+ animals
(Figure 5H and 5I, respectively) with signs of myopathy (in-
flammation, degenerative fibres). However, these signs were
less pronounced in the CDR/Cre+ than in the CD/Cre+ mice.
Next, we investigated the expression of Ripk3, Ripk1, and
Mlkl in the QUA. As expected, no expression of Ripk3 was
observed in the Ripk3-deficient mice (CDR-cre-positive or
–negative; Figure 6). Expression of Ripk1, Ripk3, and Mlkl
was higher in the CD-cre+ animals compared with the CD-
Cre-negative mice (5.2-fold, 3.1-fold, and 2.9-fold for Ripk1,
Ripk3, and Mlkl, respectively; P < 0.0001, 0.002, and 0.005,
respectively), thus showing that DUX4 expression induces
necroptosis network activation. Interestingly, in the presence
of Cre, the absence of Ripk3 did not modify or only slightly
modify the global mRNA levels of Ripk1 and Mlkl (CDR/Cre+
vs. CD/Cre+; Figure 6). However, the expression levels of
two genes downstream of DUX4 were reduced in the
CDR/Cre+ compared with the CD/Cre+ animals: by 3.1-fold
(P = 0.02) and 2.1-fold (P = 0.0005) for Tm7sf4 and mDuxbl,
respectively. Expression levels of Wfdc3 remained
Figure 5 In vivo DUX4-mediated toxicity leading to weight loss is triggered by Ripk3. (A) Variation of the total body weight gain (in percentage) from
the beginning of treatment to animal death. (B) Total running time was measured on a 15° angled treadmill system. (C and D) Weights of the tibialis
anterior (TA) and quadriceps (QUA) in the different models. N = 4–8 animals per group. Male (C) or female (D). Six-week-old animals were given a 2 day
treatment of 10 mg/kg tamoxifen delivered intraperitoneally, and the mice were killed 5 days after the last injection. CD: DUX4/+ animals; CDR:
DUX4/+Ripk3/. Data are presented as means ± standard deviation; ****: P < 0.0001; **: P < 0.01; *: P < 0.05 by one-way analysis of variance
with Dunnett’s post hoc test. (E) The quadriceps muscles (female only) were sectioned and labelled with laminin, and the min Feret was calculated for
each muscle fibre. (F and G) The min Feret average (F) and the ratio min Feret/Feret were calculated in the quadriceps of CD- and CDR-Cre+ females.
(H and I) Haematoxylin and eosin staining of CD-Cre+ (H) and CDR-Cre+ (I) muscle cross sections.
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unchanged. As expected, in the absence of Cre, genes down-
stream of DUX4 are not expressed.
RIPK3 deficiency ameliorates muscle phenotype of
DUX4-expressing mice
We next questioned whether Ripk3 depletion ameliorates
muscle phenotype after DUX4 expression. We investigated
the presence of an inflammatory response and measured
the muscle area infiltrated by macrophages using a CD68 an-
tibody. Ripk3/ CD mice (CDR) had over seven-fold de-
crease (P = 0.039) compared with RIPK3-competent CD mice
(Figure 7A), indicating a role of RIPK3 in inflammatory re-
sponse to DUX4 expression. Myonecrosis was also investi-
gated by IgG uptake labelling. The percentage of
IgG-positive area was four-fold decreased in CDR mice
(P = 0.007) (Figure 7B). Finally, we measured the percentage
of nuclear DNA fragmentation in both the CD and CDR quad-
riceps muscles. We observed 30 ± 9% of fragmented nuclei in
the Ripk3-negative animals compared with 40 ± 8% in the
Ripk3-competent animals (Figure S6), which is not statistically
different (P = 0.18, T-test). This result shows that inhibition of
necroptosis is not accompanied by a modification of the num-
ber of apoptotic nuclei. RIPK3 deficiency reduces
inflammation-mediated muscle damage and ameliorates the
muscle phenotype of DUX4-expressing mice, which demon-
strates the role of necroptosis in DUX4-mediated toxicity.
Discussion
These studies demonstrate the involvement of the
necroptosis pathway in the DUX4-mediated cells death.
Necroptosis is a cellular response to a stress that can be
caused by several triggers including inflammation, and mus-
cle inflammation has been reported in up to 1/3 of skeletal
muscle FSHD biopsies.29 Transient expression of DUX4 was
previously shown to induce many genes involved in
inflammation.30 However, it was recently proposed that cell
death may not be the consequence of inflammation but
rather its cause, and cell death may precede or trigger the in-
flammatory response.31 Further studies are required to deter-
mine to what extent cell death triggers or causes
inflammation in DUX4-expressing cells/muscles.
Previously, a possible pro-apoptotic role of DUX4 was pro-
posed, based on (i) a caspase 3/7 activity found after DUX4
overexpression in vitro,10,32 (ii) the presence of
TUNEL-positive nuclei in Xenopus embryos overexpressing
DUX4,33 (iii) the activation of a p53-dependent cell death ob-
served after DUX4 overexpression in mouse muscles and
p53-knockout mouse background suppressed AAV-DUX4
toxicity,13 (iv) the decrease of caspase 3/7 activation after
treatment of FSHD myotubes with p53 pathway inhibitors,12
and (v) bio-informatics analysis.11,18,34 DUX4-expressing cells
have been also described to be more susceptible to oxidative
stress-induced death.10,35–37 However, the role of p53 in
Figure 6 Expression of necroptotic and DUX4-network genes in the CD mice. Ripk3, Ripk1, and Mlkl and Tm7sf4, Duxbl, and Wfdc3 were measured in
the quadriceps. Six-week-old female mice were given a 2 day treatment of 10 mg/kg tamoxifen delivered intraperitoneally, and the mice were killed
5 days after the last injection. N = 2 to 5 muscles per group. CD: DUX4/+ animals; CDR: DUX4/+Ripk3/. Data are presented as means ± standard
deviation; ****: P < 0.0001; ***: P < 0.001; **: P < 0.01; *: P < 0.05 by one-way analysis of variance with Tukey’s post hoc test.
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DUX4 toxicity is under debate, and recent experiments have
shown that p53 genes do not respond to DUX4 expression
and p53 status does not impact DUX4-mediated death both
in vitro and in vivo.15 Moreover, the addition of antioxidant
to the cells decreased DUX4 toxicity rather than rescued
them,10 and supplementation with antioxidants in
FSHD patients improved only very slightly the maximum
voluntary contraction and endurance of the quadriceps
muscles.38
Here, we clearly demonstrated that DUX4 mediates a
necroptosis-dependent cell death. In vitro, the addition of
the Z-VAD pan-caspase inhibitor to the iC2C12-DUX4
myotubes did not increase cell survival, suggesting a limited
role of apoptosis in myotube death. The involvement of
necroptosis was established by the addition of the GSK’872
RIPK3 inhibitor (in combination with Z-VAD) that leads to a
two-fold increase of the number of viable cells. Interestingly,
in iC2C12 myoblasts, Ripk1 is the main regulator of
necroptosis pathway as a 20% increase of viable cells is ob-
served in the presence of necrostatin-1. Ripk3 is also involved
because there is 10% more viable cells in the presence of
GSK’872. Again, our data suggest that apoptosis does not par-
ticipate in cell death and the addition Z-VAD did not modify
the percentage of viable cells. This shows that cell death
mechanisms are different in myoblasts and myotubes and re-
sults obtained on myoblasts cannot be extrapolated to
myotubes and even less to mature muscle fibres.
In vivo, we created a new transgenic and viable mouse
model lacking Ripk3 and expressing DUX4 only after
tamoxifen injection. We chose to target Ripk3 because
Ripk1-deficient mice show perinatal lethality.39 We observed
that Ripk3 deficiency reduces the weight loss observed
after DUX4 expression but does not rescue it. This
demonstrated the involvement of Ripk3 in vivo and suggested
Figure 7 Ripk3 deficiency ameliorates muscle phenotype in mouse. Representative images of transversed sections of mouse quadriceps labelled with
Laminin and CD68 (A) or Laminin and IgG uptake (B). Quantification of CD68- (C) or IgG-uptake- (D) positive areas. Scale bar 200 μm. Data represent
the mean ± standard error of the mean on three to five animals per group. CD: DUX4/+ animals; CDR: DUX4/+Ripk3/. The Student’s T-test was
performed. *P < 0.05.
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that Ripk3-independent pathways are also responsible for
cell death.
The next step is to evaluate the involvement of necroptosis
in FSHD patients. In one hand, the necroptosis pathway has
been described to play a role in the pathogenesis of various
pathologies across the body including pulmonary, cardiovas-
cular, renal, hepatic, or neurologic systems (for review, see
previous works20,40). But in the other hand, regulated cell
death, including necroptosis, preserves organ homeostasis
by removing the cells that have been damaged beyond re-
covery. Regulated cell death is activated when the cells fail
to repair damage and restore cellular homeostasis. In the
case of DUX4 expression, one can imagine that the cascade
of misregulated genes leads to the activation of necroptosis
and to cell death eventually, as suggested by our experi-
ments in the iC2C12 cells. However, in the iC2C12 cells, each
cell carries the DUX4 gene, which can be activated upon
doxycycline addition, leading to a relatively high expression
of DUX4. In FSHD muscle, DUX4 expression occurs in burst
and a lower expression is expected, which is in agreement
with the slow disease progression observed in FSHD patients.
This difference in DUX4 levels in cells and muscle biopsies
could lead to different cell mechanisms and needs to be
experimentally validated. These results open new avenues
of research for skeletal muscle diseases and for FSHD in
particular.
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Figure S1. Expression of Wfdc3, Duxbl and Snx30 after addi-
tion different concentration of Dox in iC2C12-DUX4 myo-
blasts. Data represents the mean ± SD on 3 independent
experiments and are presented as means ± SD; ****:
P < 0.0001; ***: p < 0.001; **: p < 0.01; *: p < 0.05 by
one-way ANOVA with Dunnett’s post hoc test
Figure S2. (A) The presence of DMSO induced a non-specific
increase of cell survival. (B) Caspase 3/7 activity increased af-
ter DUX4 expression and is correctly inhibited in the presence
of Z-VAD
Figure S3.MF20 staining on iC2C12 cells after 4 days of differ-
entiation. At Day 4 of differentiation, cells were stained with
MF20 antibody recognizing all the myosin heavy chain and
counterstained with 40,6-diamidino-2-phenylindole. Fusion
index was calculated as described in Krom et al. 2012. Fusion
index was 20.3%. Scale bar: 200 mm
Figure S4. Several DUX4 downstream genes (Wfdc3, Duxbl
and Snx30) are increased in a dose dependent manner after
addition of Dox in iC2C12-DUX4 myotubes. Data represents
the mean ± SD on 3 independent experiments and are pre-
sented as means ± SEM; ****: P < 0.0001; ***: p < 0.001;
**: p < 0.01; *: p < 0.05 by one-way ANOVA with Dunnett’s
post hoc test
Figure S5. creation of the new transgenic CDR (DUX4/
+Rip/) cre-negative or –positive mouse model
Figure S6. quadriceps sections were labelled for DNA frag-
mentation using the TACS•XL®-DAB In Situ Apoptosis Detec-
tion Kit (Trevigen), according to the manufacturer
instructions. At least 2000 nuclei were analyzed per section.
Data represents the mean ± SEM on 3–5 animals/group. CD:
DUX4/+ animals; CDR: DUX4/+Ripk3/. Student T-Test
was performed. P > 0.5.
Table S1. Supporting Information
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